摘要
目的:观察自拟鹿角壮督汤对强直性脊柱炎(AS)炎性因子影响及临床疗效。方法:将80例AS患者随机分为对照组和治疗组,每组40例。对照组给予塞来昔布胶囊口服,治疗组在对照组治疗基础上加用鹿角壮督汤,疗程12周。疗程结束后,观察两组患者的临床疗效及治疗前后血清学炎性指标C反应蛋白(CRP)、红细胞沉降率(ESR)、白介素-6(IL-6)、肿瘤坏死因子-α(TNF-α),强直脊柱炎功能指数(BASFI)、强直脊柱炎疾病活动指数(BASDAI)、强直性脊柱炎计量学指数(BASMI),强直性脊柱炎疾病活动评分(ASDAS),脊柱活动度(Schober)试验、指地距、枕墙距、胸廓扩张度测量值变化情况。结果:①最终完成试验治疗组40例,对照组39例。②治疗组总有效率90.00%,对照组总有效率84.62%;两组临床疗效比较,差异有统计学意义(P<0.05)。③治疗后,两组CRP、ESR、IL-6、TNF-α较治疗前降低(P<0.05);组间治疗后比较,治疗组CRP、ESR、IL-6、TNF-α较对照组明显降低(P<0.05)。④治疗后,两组BASFI、BASDAI、BASMI评分均较治疗前降低(P<0.05);组间治疗后比较,治疗组BASFI、BASDAI、BASMI评分较对照组明显降低(P<0.05)。⑤治疗后,两组ASDAS-CRP、ASDAS-ESR评分均较治疗前降低(P<0.05);组间治疗后比较,治疗组ASDAS-CRP、ASDAS-ESR评分较对照组明显降低(P<0.05);⑥治疗后,两组Schober试验测量值较治疗前增加、指地距降低(P<0.05);组间治疗后比较,治疗组Schober试验测量值、指地距均优于对照组(P<0.05);枕墙距及胸廓扩张度组内及组间比较均未见明显改善(P>0.05)。结论:鹿角壮督汤能够有效下调AS患者炎症因子水平,降低BASFI、BASDAI、BASMI、ASDAS-CRP、ASDAS-ESR评分,改善Schober试验及指地距离,疗效显著,安全可靠。
Objective:To observe the effect of Lujiao Zhuangdu Decoction on inflammatory factors of ankylosing spondylitis(AS)and its clinical efficacy.Methods:A total of 80 AS patients were randomly divided into the control group and the treatment group,40 cases in each group.The control group was given oral celecoxib capsules,and the treatment group was given Lujiao Zhuangdu Decoction on the basis of the control group,and the course of treatment was 12 weeks.After the course of treatment,the clinical efficacy of the two groups and the levels of serum inflammatory indexes CRP,ESR,IL-6,TNF-α,ankylosing spondylitis functional index(BASFI),ankylosing spondylitis disease activity index(BASDAI),ankylosing spondylitis metrology index(BASMI),ankylosing spondylitis disease activity score(ASDAS),spinal range of motion(Schober)test,finger-to-ground distance,pillow-to-wall distance,and changes in thoracic expansion measurements were observed.Results:①Finally,40 cases in the experimental treatment group and 39 cases in the control group were completed.②The total effective rate in the treatment group was 90.00%,and the total effective rate in the control group was 84.62%;the difference in clinical efficacy between the two groups was statistically significant(P<0.05).③After treatment,the CRP,ESR,IL-6 and TNF-αin the two groups were lower than those before treatment(P<0.05).Compared with the two groups after treatment,CRP,ESR,IL-6 and TNF-αin the treatment group were significantly lower than those in the control group(P<0.05).④After treatment,the BASFI,BASDAI,and BASMI scores of the two groups were all lower than those before treatment(P<0.05).Compared with the two groups after treatment,the BASFI,BASDAI,and BASMI scores in the treatment group were significantly lower than those in the control group(P<0.05).⑤After treatment,the scores of ASDAS-CRP and ASDAS-ESR in the two groups were decreased compared with those before treatment(P<0.05).Compared with the two groups after treatment,the scores of ASDAS-CRP and ASDAS-ESR in the
作者
张娜
沈丕安
陈薇薇
ZHANG Na;SHEN Pi’an;CHEN Weiwei(Rheumatology Department,Shanghai Hospital of Traditional Chinese Medicine,Shanghai University of Traditional Chinese Medicine,Shanghai 200071,China)
出处
《上海中医药大学学报》
CAS
2023年第3期30-34,共5页
Academic Journal of Shanghai University of Traditional Chinese Medicine
基金
上海市卫健委名老中医学术经验研究工作室建设项目(ZYSNXD-CC-MZY048)
上海市中医医院未来计划项目(WLJH2021ZY-MZY037)。
关键词
鹿角壮督汤
强直性脊柱炎
炎症因子
病情活动度
临床疗效
Lujiao Zhuangdu Decoction
ankylosing spondylitis
inflammatory factors
disease activity
clinical efficacy
